SequelSEC

ABVC BIOPHARMA, INC. ABVC

Pharmaceutical Preparations · CIK 0001173313 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
-$499.95K
Fiscal year ended 2025-12-31
Operating income
-$2.20M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

ABVC BIOPHARMA, INC. (ABVC) reported revenue of -$499.95K and net income of -$2.77M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from ABVC BIOPHARMA, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ABVC BIOPHARMA, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312025-09-302024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-31
Revenue-$499.95K$795.95KUnavailable$389.28K$117.14K$1.20K$2.16K$15.88K$6.11K$128.27K
Cost of revenueUnavailableUnavailableUnavailable$296$190$277$139.21K$29.61K$72.98K$60.24K
Gross profitUnavailable$795.95KUnavailable$388.98K$116.95K$928-$137.04K-$13.73K-$66.87K$68.04K
Operating income-$2.20M-$1.96MUnavailable-$302.32K-$860.11K-$2.84M-$511.84K-$2.15M-$2.19M-$1.91M
Net income-$2.77M-$2.04MUnavailable-$394.77K-$942.34K-$2.83M-$383.33K-$3.32M-$2.26M-$1.82M
Research & development$29.06K$29.89KUnavailable$37.82K$40.40K$69.07K$72.18K$141.31K$514.44K$334.98K
Weighted-average diluted sharesUnavailableshares 23.26MUnavailableshares 12.41Mshares 11.32Mshares 9.74MUnavailableshares 4.06Mshares 3.31Mshares 3.31M
Pretax income-$3.02M-$2.08MUnavailable-$487.08K-$1.16M-$2.93M-$525.00K-$3.37M-$2.23M-$1.90M
Income tax expense$0$527Unavailable$355-$110.89KUnavailable$175.31K-$999$81.70KUnavailable
Diluted EPSUnavailable$-0.09Unavailable$-0.03$-0.08$-0.29Unavailable$-0.82$-0.68$-0.55
Selling, general & administrative$783.64K$798.25KUnavailable$557.60K$653.78K$738.49K$1.53M$1.18M$1.39M$1.27M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

ABVC BIOPHARMA, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312025-09-302024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-31
Cash & equivalents$681.48K$192.07KUnavailable$137.34K$124.30K$30.49K$60.16K$500.07K$99.29K$1.13M
Total assets$21.06M$21.21MUnavailable$7.78M$8.04M$7.98M$7.78M$16.59M$9.32M$10.73M
Current assets$2.50M$3.31MUnavailable$2.17M$2.31M$1.79M$1.66M$2.49M$2.13M$3.48M
Total liabilities$7.76M$6.72MUnavailable$6.44M$6.50M$6.52M$6.53M$7.53M$9.69M$9.00M
Current liabilities$6.16M$6.54MUnavailable$6.25M$6.25M$6.18M$6.10M$5.36M$5.77M$5.07M
Total equity incl. NCI$13.30M$14.50MUnavailable$1.34M$1.54M$1.46M$1.25M$9.06M$1.36M$1.73M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailable$11.46KUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable$1.53K$1.53K$1.53K$839.98K$1.53K$12.36K$124.13K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

ABVC BIOPHARMA, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312025-09-302024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-31
Operating cash flow-$587.58KUnavailableUnavailable$60.23K-$211.42K-$955.82K-$430.46K-$1.36M-$899.83K-$1.50M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0UnavailableUnavailableUnavailable
Investing cash flow-$29.65KUnavailableUnavailable$44.82KUnavailableUnavailable$154.17K-$73.78KUnavailableUnavailable
Financing cash flow$1.08MUnavailableUnavailable-$81.36K$802.16K$924.15K$38.42K$1.66M-$31.59K$2.21M
Net change in cash$473.07KUnavailableUnavailable$27.10K$83.77K-$57.78K-$404.16K$378.75K-$1.05M$400.15K
Stock-based compensation$1.39M$1.14MUnavailable$95.88K$282.88K$2.03M-$1.22M$817.74K$225.74K$366.49K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$7.46K$7.00K$6.49K

Derived

ABVC BIOPHARMA, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312025-09-302024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-$430.46KUnavailableUnavailableUnavailable
Gross marginUnavailable100.0%Unavailable99.9%99.8%77.0%-6329.8%-86.4%-1094.6%53.0%
Operating marginUnavailableUnavailableUnavailable-77.7%-734.2%-235539.8%-23641.3%-13566.3%-35911.6%-1486.0%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-19882.8%UnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable24.6%241.5%168600.1%-56537.5%5148.2%3695.2%285.7%
Current ratio0.41x0.51xUnavailable0.35x0.37xUnavailable0.27x0.46x0.37x0.69x
Revenue YoY growthUnavailable104.5%Unavailable2350.7%1817.5%-99.1%-99.6%-62.4%-98.0%399.9%
Net marginUnavailableUnavailableUnavailable-101.4%-804.4%-235203.2%-17705.7%-20885.9%Unavailable-1421.7%
R&D / revenueUnavailableUnavailableUnavailable9.7%34.5%5731.6%3334.2%889.6%8421.1%261.1%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable0.0%UnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ABVC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-18View SEC filing
10-Q/A · Filed 2026-03-03View SEC filing
10-K · Filed 2026-03-03View SEC filing
10-Q · Filed 2025-11-03View SEC filing
10-Q · Filed 2025-08-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ACAD ACET ACRS ACRV ACTU

Reconciliation checks needing review

3 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationinconsistent2024-12-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-12-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationreview2023-06-30

Difference 1729028 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.